To break the barrier, NMDP began a clinical trial in September 2021 to determine the effectiveness of transplants where the donor shared less than eight HLA markers in common with the recipient.

Caribou's Allogeneic CAR-T Therapy: Analyzing HLA Matching And CB-010's Clinical Performance Jul. 05, 2024 3:18 PM ET Caribou Biosciences, Inc. (CRBU) Stock ALLO, CRBU 19 Comments BioCGT Investor ...

Mehta, R. S., Petersdorf, E. W., Wang, T., Spellman, S. R., & Lee, S. J. (2024). Interplay between donor age and HLA-DP matching in 10/10 HLA-matched unrelated donor HCT. Blood Advances, bloodadvances ...

NMDP’s network of transplant centers, many of which participate in CIBMTR trials, are bringing new research to light that is challenging previously established stem cell transplantation science.

Matching donors for stem cell transplantation demands both precision and speed, especially as requests for high-resolution human leukocyte antigen (HLA) data grow. As labs adapt to higher workloads ...

"HLA matching is the main way of risk stratifying when it comes to kidney transplant," said Cherukuri. "Even with a good HLA match, recipients must take immunosuppressant drugs for the rest of ...

Matching donors for stem cell transplantation demands both precision and speed, especially as requests for high-resolution human leukocyte antigen (HLA) data grow. As labs adapt to higher workloads ...

NMDP’s network of transplant center partners, many of which participate in CIBMTR trials, are bringing new research to light that is challenging previously established stem cell transplantation ...